Need Help?

RNA-seq

RNA-seq of primary and metastatic sites from highly clinically annotated HGSC samples. Samples were obtained pre-treatment based on a laparoscopic triage algorithm from patients who underwent R0 tumor debulking, or received neoadjuvant chemotherapy (NACT) with excellent (ER) or poor response(PR).

Request Access

Ovarian cancer Omics DAC

These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC): The University of Texas MD Anderson Cancer Center 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) prior to any significant changes to the protocol for the Project. 14. The User Institution will notify DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC) may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than DAC FOR HIGH-GRADE SEROUS OVARIAN CANCER (MDACC). In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001003804 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00002550088 bam 4.2 GB
EGAF00002550089 bam 5.1 GB
EGAF00002550090 bam 6.6 GB
EGAF00002550091 bam 9.3 GB
EGAF00002550092 bam 5.1 GB
EGAF00002550093 bam 9.6 GB
EGAF00002550094 bam 4.8 GB
EGAF00002550095 bam 2.4 GB
EGAF00002550096 bam 6.1 GB
EGAF00002550097 bam 8.8 GB
EGAF00002550098 bam 5.7 GB
EGAF00002550099 bam 6.0 GB
EGAF00002550100 bam 4.1 GB
EGAF00002550101 bam 3.3 GB
EGAF00002550102 bam 7.4 GB
EGAF00002550103 bam 6.3 GB
EGAF00002550104 bam 5.9 GB
EGAF00002550105 bam 5.1 GB
EGAF00002550106 bam 3.3 GB
EGAF00002550107 bam 5.3 GB
EGAF00002550108 bam 6.4 GB
EGAF00002550109 bam 7.1 GB
EGAF00002550110 bam 1.7 GB
EGAF00002550111 bam 4.1 GB
EGAF00002550112 bam 8.2 GB
EGAF00002550113 bam 5.9 GB
EGAF00002550114 bam 4.9 GB
EGAF00002550115 bam 3.4 GB
EGAF00002550116 bam 2.9 GB
EGAF00002550117 bam 5.8 GB
EGAF00002550118 bam 4.9 GB
EGAF00002550119 bam 7.9 GB
EGAF00002550120 bam 7.1 GB
EGAF00002550121 bam 6.5 GB
EGAF00002550122 bam 5.1 GB
EGAF00002550123 bam 8.6 GB
EGAF00002550124 bam 5.9 GB
EGAF00002550125 bam 4.2 GB
EGAF00002550126 bam 7.3 GB
EGAF00002550127 bam 6.5 GB
EGAF00002550128 bam 5.0 GB
EGAF00002550129 bam 8.2 GB
EGAF00002550130 bam 6.2 GB
EGAF00002550131 bam 6.8 GB
EGAF00002550132 bam 5.4 GB
EGAF00002550133 bam 8.2 GB
EGAF00002550134 bam 7.1 GB
EGAF00002550135 bam 4.4 GB
EGAF00002550136 bam 4.2 GB
EGAF00002550137 bam 3.2 GB
EGAF00002550138 bam 7.1 GB
EGAF00002550139 bam 5.6 GB
EGAF00002550140 bam 3.0 GB
EGAF00002550141 bam 6.7 GB
EGAF00002550142 bam 6.6 GB
EGAF00002550143 bam 6.6 GB
EGAF00002550144 bam 4.9 GB
EGAF00002550145 bam 5.9 GB
EGAF00002550146 bam 3.7 GB
EGAF00002550147 bam 6.6 GB
EGAF00002550148 bam 5.0 GB
EGAF00002550149 bam 6.3 GB
EGAF00002550150 bam 7.3 GB
EGAF00002550151 bam 8.7 GB
EGAF00002550152 bam 7.3 GB
EGAF00002550153 bam 4.7 GB
EGAF00002550154 bam 4.9 GB
EGAF00002550155 bam 2.9 GB
EGAF00002550156 bam 855.1 MB
EGAF00002550157 bam 1.6 GB
EGAF00002550158 bam 3.3 GB
EGAF00002550159 bam 7.1 GB
EGAF00002550160 bam 6.0 GB
EGAF00002550161 bam 8.2 GB
74 Files (418.3 GB)